| Gain Therapeutics–VitaTech: investment, 201902 financing round Series A totalling €2.5m incl €1.1m from new investor VitaTech SA |
2019-02-19 |
| Qiagen–Curetis: bioinformatics, 201902– license excl to use ARESdb for general bioinformatics research offerings + services for AMR research |
2019-02-18 |
| S-Biomedic–DSM: investment, 201902 financing round Series A 2nd closing totalling €2m incl new investor DSM Venturing |
2019-02-18 |
| S-Biomedic–SEVERAL: investment, 201902 financing round Series A 2nd closing €2m from new investor DSM Venturing + existing investor investiere.ch |
2019-02-18 |
| S-Biomedic–Verve Capital Partners: investment, 201902 financing round Series A 2nd closing totalling €2m incl existing investor investiere.ch |
2019-02-18 |
| Arvelle Therapeutics–Andera Partners: investment, 201902 financing round Series A totalling $180m incl investor Andera Partners |
2019-02-14 |
| Arvelle Therapeutics–BRV Capital: investment, 201902 financing round Series A totalling $180m incl investor BRV Capital Management |
2019-02-14 |
| Arvelle Therapeutics–H.I.G. Capital: investment, 201902 financing round Series A totalling $180m incl investor H.I.G. BioHealth Partners |
2019-02-14 |
| Arvelle Therapeutics–Life Sciences Partners: investment, 201902 financing round Series A totalling $180m incl lead investor LSP |
2019-02-14 |
| Arvelle Therapeutics–NovaQuest Capital: investment, 201902 financing round Series A totalling $180m incl investor NovaQuest Capital Management |
2019-02-14 |
| Arvelle Therapeutics–Sam Brown: public relations, 201902 service existent by Sam Brown Inc |
2019-02-14 |
| Arvelle Therapeutics–SEVERAL: investment, 201902–202005 financing round Series A $180m with global investor syndicate |
2019-02-14 |
| Arvelle Therapeutics–SK Group: cenobamate, 201902– license excl for Europe $110m upfront + $430m milestones + royalties from SK Biopharmaceuticals |
2019-02-14 |
| Novartis–AbCellera: therapeutic antibodies, 201902– collab discovery use of AbCellera technology + screening for up to ten targets |
2019-02-14 |
| Plasmion–Bavaria (govt): investment, 201902 financing round totalling almost €1m from HTGF + BayBG + business angel |
2019-02-14 |
| Plasmion–High-Tech Gründerfonds: investment, 201902 financing round totalling almost €1m from HTGF + BayBG + business angel |
2019-02-14 |
| Plasmion–PERSON: investment, 201902 financing round totalling almost €1m from HTGF + BayBG + business angel |
2019-02-14 |
| Plasmion–SEVERAL: investment, 201902 financing round almost €1m from HTGF + BayBG + business angel |
2019-02-14 |
| Boehringer–IBM: blockchain technology, 201902– collab to integrate blockchain technology into clinical trials of BI Canada + IBM Canada |
2019-02-12 |
| Andrew Alliance–Sartorius: electronic pipettes, 201902 collab co-developm + launch Pipette+ system combining Picus hardware with OneLab s/w |
2019-02-08 |
| Symrise–SEVERAL: investment, 201902 capital increase €400m with 5.614m new shares at €71.25/share to fund acquisition of ADF/IDF |
2019-02-08 |
| Galapagos–Evotec: antifibrotic, 201902– collab + ww commercial rights for Galapagos to small-molecule programme for fibrotic diseases |
2019-02-07 |
| Denothex–Optimapharm: investment, 201902 acquisition of Denothex Ltd by Optimapharm |
2019-02-06 |
| Waters–Andrew Alliance: automated liquid handling technology, 201902–collab new solutions for LC-MS research |
2019-02-06 |
| Bruker–Genedata: bioinformatics, 201902 collab product integration Bruker new Ready-to-Run partner |
2019-02-05 |
| Numares–Mayo Clinic: NMR spectroscopy, 201902– collab developm metabolomics-based NMR clinical tests with Mayo Clinic Labs |
2019-02-05 |
| Roche–Xencor: cancer immunotherapy, 201901– collab developm + commerc ww $120m upfront + milestones + profit share IL-15 cytokine drugs Genentech |
2019-02-05 |
| Macherey-Nagel–Andrew Alliance: automated liquid handling technology, 201902–collab co-marketing NucleoBond kits with OneLab s/w + Andrew+ robot |
2019-02-04 |
| United Kingdom (govt)–Qiagen: bioinformatics, 201902– supply Genomics England selects QCI for genome sequencing project of NHS |
2019-02-04 |
| ADF/IDF–Symrise: investment, 201901– acquisition $900m by Symrise ANNOUNCED |
2019-01-31 |
| Apceth–Hitachi: investment, 201901–201904 acquisition €75.5m 100% of Apceth Biopharma GmbH from Apceth GmbH by Hitachi Chemical |
2019-01-31 |
| Bayer–Univ Kyoto: drug discovery, 201901– collab €na research alliance for drug target discovery for pulmonary diseases incl IPF |
2019-01-31 |
| Dewpoint Therapeutics–6 Dimensions Capital: investment, 201901 financing round Series A totalling $60m incl co-investor 6 Dimensions Capital |
2019-01-30 |
| Dewpoint Therapeutics–Alexandria Real Estate: investment, 201901 financing round Series A totalling $60m incl co-investor Alexandria Ventures |
2019-01-30 |
| Dewpoint Therapeutics–Bayer: investment, 201901 financing round Series A totalling $60m incl co-investor Leaps by Bayer |
2019-01-30 |
| Dewpoint Therapeutics–EcoR1 Capital: investment, 201901 financing round Series A totalling $60m incl co-investor EcoR1 Capital |
2019-01-30 |
| Dewpoint Therapeutics–Polaris Partners: investment, 201901 financing round Series A totalling $60m incl lead investor Polaris Partners |
2019-01-30 |
| Dewpoint Therapeutics–Samsara BioCapital: investment, 201901 financing round Series A totalling $60m incl co-investor Samsara BioCapital |
2019-01-30 |
| Dewpoint Therapeutics–SEVERAL: investment, 201901 financing round Series A $60m led by Polaris Partners |
2019-01-30 |
| Medizinsches Labor Hannover–Labor Limbach: investment, 201901 acquisition 100% of MLH by Limbach Gruppe SE PENDING |
2019-01-26 |
| MAB Discovery–BioNTech: investment, 201901–201903 acquisition €na of Antibody Generation Unit of MAB Discovery by BioNTech |
2019-01-23 |
| CRISPR Therapeutics–Minapharm: gene transfer technology, 201901– collab + license €na with ProBioGen to develop in vivo delivery technology for CRISPR |
2019-01-22 |
| Scailyte–SEVERAL: investment, 201901 seed financing round CHF2.75m incl new investors Swisscom Ventures + Zürcher Kantonalbank |
2019-01-22 |
| Scailyte–Swisscom: investment, 201901 seed financing round totalling CHF2.75m incl new investors Swisscom Ventures + Zürcher Kantonalbank |
2019-01-22 |
| Scailyte–Zürcher Kantonalbank: investment, 201901 seed financing round totalling CHF2.75m incl new investors Swisscom Ventures + Zürcher Kantonalbank |
2019-01-22 |
| Link Health–Marinomed: drug delivery technology, 201901– collab registration + distribution of Marinosolv products in China by Link Health |
2019-01-21 |
| Medison Pharma–Alnylam: RNAi therapeutics, 201901– commcercialisation excl of Onpattro + other RNAi drugs from Alnylam in Israel |
2019-01-21 |
| Miltenyi Biotec–Univ Duisburg-Essen: imaging technology, 201901 acquisition process for opitcal clearing of biological samples for miccrosopy |
2019-01-17 |
| Mologen–SEVERAL: credit, 201901–202701 convertible bonds €2.7m at 6% incl existing shareholders |
2019-01-17 |
| Mecuris–Bavaria (govt): investment, 201901 financing round Series A totalling €3.6m incl existing investor Bayern Kapital GmbH |
2019-01-16 |
| Mecuris–High-Tech Gründerfonds: investment, 201901 financing round Series A totalling €3.6m incl existing investor HTGF |
2019-01-16 |
| Mecuris–Mulcan: investment, 201901 financing round Series A totalling €3.6m incl new investor MII Mulcan International Investments GmbH |
2019-01-16 |
| Mecuris–OTHER: investment, 201901 financing round Series A totalling €3.6m incl new investor one of largest German hospital chains |
2019-01-16 |
| Mecuris–SEVERAL: investment, 201901 financing round Series A €3.6m incl Bayern Kapital + HTGF + Vesalius Biocapital + Mulcan et al. |
2019-01-16 |
| Mecuris–Vesalius Biocapital: investment, 201901 financing round Series A totalling €3.6m incl new investor Vesalius Biocapital III SICAR |
2019-01-16 |
| United States (govt)–Valneva: Japanese encephalitis vaccine, 201901– supply $59m+$11m of Ixiaro to US DoD |
2019-01-16 |
| Boehringer–Bioharmony Therapeutics: antibiotics, 201901– collab developm of bateriophage lysins |
2019-01-15 |
| InterAx Biotech–Falcon III Ventures: investment, 201901 financing round totalling CHF3m incl co-lead investor Falcon III Ventures |
2019-01-15 |
| InterAx Biotech–SEVERAL: investment, 201901 financing round CHF3m led by Falcon III Ventures + Investiere |
2019-01-15 |
| InterAx Biotech–Verve Capital Partners: investment, 201901 financing round totalling CHF3m incl co-lead investor Investiere |
2019-01-15 |
| Cell Signaling Technology–Omni Life Science: cell research instruments, 201901– distribution of OLS’ CERO + CESY instruments by Bioké in Benelux |
2019-01-14 |
| Merck (DE)–Roche: biochemical reagents, 201901–2025 distribution extension ww excl of Roche biochemical reagents portfolio |
2019-01-14 |
| Agenus–JSR Corp: cell line development, 201901– collab expansion license to use Selexis’ SUREtechnology for production of therapeutic proteins |
2019-01-09 |
| BC Platforms–MedEngine (FI): medical data science services, 201901– collab strategic partnership to provide solutions for pharma + health sectors |
2019-01-09 |
| Denali Therapeutics–Sirion Biotech: gene delivery technology, 201901– license + collab develop AAV vectors for CNS diseases that could cross BBB |
2019-01-09 |
| CureVac–Global Health PR: public relations, 201809 service existent media relations by Global Health PR |
2019-01-08 |
| Exscientia–Evotec: investment, 201901 financing round Series B totalling $26m incl $6m from existing investor Evotec AG |
2019-01-07 |
| Exscientia–GT Healthcare Capital Partners: investment, 201901 financing round Series B totalling $26m incl new investor GT Healthcare Capital Partners |
2019-01-07 |
| Exscientia–SEVERAL: investment, 201901 financing round Series B $26m incl Celgene Corp + GT Heallthcare Capital Partners + Evotec |
2019-01-07 |
| F2G Ltd–Optimum Strategic Communications: public relations, 201901 service existent by Optimum |
2019-01-07 |
| Immunic–Bavaria (govt): investment, 201901–201904 financing round totalling €26.7m incl existing investor Bayern Kapital |
2019-01-07 |
| Immunic–Fund+: investment, 201901–201904 financing round totalling €26.7m incl investor Fund+ |
2019-01-07 |
| Immunic–High-Tech Gründerfonds: investment, 201901–201904 financing round totalling €26.7m incl existing investor HTGF |
2019-01-07 |
| Immunic–Life Sciences Partners: investment, 201901–201904 financing round totalling €26.7m incl existing investor LSP |
2019-01-07 |
| Immunic–LifeCare Partners: investment, 201901–201904 financing round totalling €26.7m incl existing investor LCP |
2019-01-07 |
| Immunic–Omega Funds: investment, 201901–201904 financing round totalling €26.7m incl investor Omega Funds |
2019-01-07 |
| Immunic–Saxony-Anhalt (govt): investment, 201901–201904 financing round totalling €26.7m incl existing investor IBG |
2019-01-07 |
| Immunic–SEVERAL: investment, 201901–201904 financing round €26.7m in connection with reverse merger to list on Nasdaq |
2019-01-07 |
| Immunic–Vital Therapeutics: investment, 201901–201904 reverse merger to list on Nasdaq with Vital Therapies renamed Immunic Inc |
2019-01-07 |
| Loxo Oncology–Lilly: investment, 201901–201902 acquisition cash tender offer $8b for $235/share |
2019-01-07 |
| N-of-One–Qiagen: investment, 201901 acquisition €na of N-of-One Inc by Qiagen |
2019-01-07 |
| Roche–Exscientia: drug discovery software, 201901– collab up to CHF67m + royalties using Centaur Chemist to design drug candidates |
2019-01-07 |
| Biogen–C4 Therapeutics: neurological drugs, 201901– collab strategic up to $415m upfront/milestones discovery small molecues for protein degradation |
2019-01-04 |
| Biogen–Skyhawk Therapeutics: neurological drugs, 201901– collab strategic $74m upfront + milestones discovery small molecues using SkySTAR platform |
2019-01-04 |
| Medigene–Helmholtz: cell therapy, 201901– license to co-stimulator to enhance TCR therapies for solid tumours from HMGU |
2019-01-04 |
| Ribon Therapeutics–Celgene: investment, 201901 financing round Series B totalling $65m incl new + co-investor Celgene Corp |
2019-01-04 |
| Ribon Therapeutics–Column Group: investment, 201901 financing round Series B totalling $65m incl existing + co-investor The Column Group |
2019-01-04 |
| Ribon Therapeutics–Deerfield: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Deerfield Management |
2019-01-04 |
| Ribon Therapeutics–Euclidean Capital: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Euclidean Capital |
2019-01-04 |
| Ribon Therapeutics–JnJ: investment, 201901 financing round Series B totalling $65m incl new + co-investorJJDC |
2019-01-04 |
| Ribon Therapeutics–Novartis: investment, 201901 financing round Series B totalling $65m incl new + lead investor Novartis Venture Fund |
2019-01-04 |
| Ribon Therapeutics–Osage Partners: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Osage University Partners |
2019-01-04 |
| Ribon Therapeutics–SEVERAL: investment, 201901 financing round Series B $65m led by Novartis Venture Fund |
2019-01-04 |
| Ribon Therapeutics–Takeda: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Takeda Ventures |
2019-01-04 |
| Ribon Therapeutics–US Venture Partners: investment, 201901 financing round Series B totalling $65m incl existing + co-investor US Venture Partners |
2019-01-04 |
| Sophia Genetics–Alychlo: investment, 201901 financing round Series E totalling $77m incl existing + co-investor Alychlo |
2019-01-04 |
| Sophia Genetics–Balderton Capital: investment, 201901 financing round Series E totalling $77m incl existing + co-investor Balderton Capital |
2019-01-04 |
| Sophia Genetics–Eurazeo: investment, 201901 financing round Series E totalling $77m incl new + co-investor Idinvest Partners |
2019-01-04 |
| Sophia Genetics–Generation Investment Management: investment, 201901 financing round Series E totalling $77m incl new + lead investor Generation |
2019-01-04 |
| Sophia Genetics–SEVERAL: investment, 201901 financing round Series E $77m incl new + lead investor Generation Investment Management LLP |
2019-01-04 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 ... 38 39 40 41 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
